Difference between revisions of "Danicopan (ALXN-2040)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== Complement factor D inhibitor ==Preliminary data== ===Paroxysmal nocturnal hemoglobinuria (PNH)=== #'''ALPHA:'...") |
(No difference)
|
Latest revision as of 01:24, 19 January 2024
Mechanism of action
Complement factor D inhibitor
Preliminary data
Paroxysmal nocturnal hemoglobinuria (PNH)
- ALPHA: Lee JW, Griffin M, Kim JS, Lee Lee LW, Piatek C, Nishimura JI, Carrillo Infante C, Jain D, Liu P, Filippov G, Sicre de Fontbrune F, Risitano A, Kulasekararaj AG; ALXN2040-PNH-301 Investigators. Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial. Lancet Haematol. 2023 Dec;10(12):e955-e965. link to original article PubMed NCT04469465